VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
Titel:
VP7-2022: An ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): A double-blind, randomized, placebo-controlled, phase III trial
Auteur:
Mirza, M.R. Wu, X. Zhu, J. Yin, R. Yang, J. Liu, J. Wang, J. Wu, L. Liu, Z. Gao, Y. Wang, D. Lou, G. Yang, H. Zhou, Q. Kong, B. Huang, Y. Chen, L. Zhen, X. Dong, J. Hou, J.